

Identity:

Title: MD.Ph.D. MSc.F.E.S.C. F.H.F.A

Family Name(s): KIPIANI

First Name(s): ZVIAD

Age: 56

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

Choose an item.

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	JERARSI CLINCI /PRESIDENT OF GEORGIAN HEART FAILURE ASSOCIATION
Department:	Head of Cardiology and Heart Failure Clinic
Address:	2° Mukhiani street
Post code / Zip:	0167
Country:	Georgia

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

Summary

Medical Doctor with 29 years' experience as a Cardiologist and Heart Failure Specialty 9 years;

Head of Cardiology Department from 2011;

Founder of Georgian Hear Failure Association and organizer First Heart Failure Forum in Georgia and First Master Course in Heart Failure in Georgia and in The Region with interactive case orientated teaching sessions for participants from Georgia, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkey and from Central Asia

Participant of different international and global Clinical Trials as a Principal Investigator;

Participant as a Speaker at many International and local Conferences and meetings including Heart Failure Meetings and conferences ;

Master of Sciences Degree from London School of Economics and Political Science.

Skill Highlights

- Strong decision maker
- Complex problem solver
- Assessing and planning treatment requirements
- Leadership and management skills
- Innovative
- Service-focused

Experience

Head of Cardiology and Heart Failure Department 01/11/2023-to present Jerarsi clinic . Tbilisi. Georgia

JERARSI Clinic –Head Of Cardiology Department 01/31/2023- to present

Head Of Cardiology and Heart Failure Department 01/10/2020-31/10/2023

American Hospital Tbilisi . Georgia

Head of Cardiovascular Department - 01/08/2011 – 30/09/2020

New Hospitals . Tbilisi. Georgia

- Head of Cardiology Department
- Evaluation Pre and Post Cardiac Surgery Patients
- Intensive care, Heart Failure Clinic
- Inpatient and outpatient care
- Diagnostics-non invasive (Echo Lab , Cardiac CT ,MRI)
- Research studies
- Teaching activities

Consultant Cardiologist - 01/05/2009 - 30/07/2011

Medical Center "Cito", Tbilisi, Georgia

Consultant Cardiologist - 03/1999 - 07/2011

Tbilisi State Medical University Clinic N1, Tbilisi, Georgia

Awards:

European Cardiologist (Diploma-2002)

Fellow of European Society of Cardiology-F.E.S.C. (2003)

Fellow of Heart Failure Association –FHFA

EDUCATION:

Postgraduate Course in Heart Failure London-2020-2022

The Executive MSc in Health Economics, Outcomes and Management in Cardiovascular Sciences London School Of Economics and Political Science. MSc Diploma
London. UK (2016-2018)

Postgraduate Course in Heart Failure (2 Years 8 Modules) University Hospital Zurich,
University Heart Center Zurich

European Society Of Cardiology, European Heart Academy, Zurich Heart House, Zurich Switzerland (2014-2015)

University Heart Center Zurich

Clinic of Cardiology, University Hospital Zurich

Completed Clinical Training in Cardiology, Zurich Switzerland (02/02-06/02/2015)

Fellowship in Cardiology, American Austrian Foundation / Department of Cardiology
General Hospital of Salzburg, Salzburg, Austria (01/12/2013-21/12/2013)

Fellowship in Cardiology, American Austrian Foundation and the Department of Cardiology
General Hospital of Salzburg, Salzburg, Austria (28/11-23/12/2011)

Visiting Doctor in The Department of Cardiothoracic Surgery
Division of Research and Education, Cleveland Clinic, Florida, USA (30/07-30/08/2010)

International Post-Graduate Clinical Course, Department of Cardiology
Mount Sinai Medical Center, Miami, Florida, United States of America (01/07-30/07/2010)

Postgraduate Training Course in Cardiology Tel Aviv University Sackler Faculty of Medicine
School of Continuing Medical Education, Ministry of
Foreign Affairs, Acknowledge Certificate, Tel Aviv,
Israel (19/01-3/04/2009)

Fellowship in Cardiology, Department of Cardiology University Hospital of Innsbruck
The American Austrian Foundation, Innsbruck, Austria (04/02-30/03/-2007)

Fellowship in Echocardiography, Mayo Clinic, Rochester, Minnesota, United States of America (01/10/05-31/09/06)

38th International Teaching Seminar On Cardiovascular Epidemiology and Prevention WHO
Tunisia
(21/08/05-2/09/05)

**Salzburg Weill Cornell Seminar In Cardiology, Weill Medical College Of Cornell University,
Salzburg, Austria (19-25/6/05)**

Fellowship Training in Interventional Cardiology, Onassis Cardiac Surgery Center, Athens, Greece (01/09-1/12/1999)

Postgraduate clinical and research study (Fellowship) in Cardiology
Tbilisi State Medical University Clinic N1, Department of Cardiology. Tbilisi, Georgia. Diploma (1996 – 1999)

**Tbilisi State Medical University Clinics N1, Department of Cardiology.
Tbilisi, Georgia. Postgraduate Trainings in General Cardiology.
Specialization Certificate (1994 – 1996)**

Tbilisi State Medical University Clinic N1, Department of Internal Medicine, Tbilisi, Georgia.
Internship in Internal Medicine
Certificate (1993 – 1994)

Tbilisi State Medical University. Tbilisi, Georgia. Faculty of General Medicine. MD Diploma.
(1987 – 1993)

Clinical Trials

INNOVALVE TWIST-GE CLINICAL TRIAL 2021-2022

Protocol: [RIVAROXDVT3002](#)

Janssen Research and Development, LLC.

Patient Assessment of Rivaroxaban Versus Placebo in Reducing

Post-Discharge Venous Thrombo-Embolic Risk (Phase 3), Study Duties: PI (2017-2019)

“A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation. Powder with Placebo on Survival in Subjects with Moderate COPD and History of or at Increased Risk For Cardiovascular Diseases.”

Phase 3, Study Duties: PI, GlaxoSmithKline and Parexel, Summit COPD and Cardiovascular Diseases (2013 – 2015)

[MK-3102-018](#) (Parexel ref: 207246)

“A randomized , Double Blind, Placebo-Controlled Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus.”

Phase 3, Study Duties: PI (2012-2014)

[MK-8835/pf-04971729](#)

“A Randomized , Double Blind, Placebo-Controlled, Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment with Ertugliflozin. Subjects with Type 2 Diabetes Mellitus and Establishment.” Vascular Disease: Phase 3, Duties in the Study: PI (2013 – 2018)

Magic - Magnesium in Coronaries (MAGIC), Study Duties: Sub Investigator (2002 - 2003)

“Hero 2 Thrombin - Specific Anticoagulation with Bivalirudin Versus Heparin in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction: the HERO-2 Randomized Trial.” Study Duties: Sub Investigator (2001-2002)

Hellas Study(Anticoagulation and Heart Failure with HFrEF), Study Duties: PI, (1999-2001)

Publications:

Early experience with the Innovalve Transcatheter Mitral Valve Replacement System

The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. National Cardiac Society Reviewer

The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019

European Journal of Heart Failure (2021)

Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program (2018)

Association

President of Georgian Heart Association

Fellow of HFA

Fellow of European Society

Cardiology

Member of Heart and Lung Transplantation

international Society

Board Member of Georgian Society of Cardiology

International Association Member of American College

Of Cardiology

Premium Professional Member American Heart

Association

Languages:

English – C2

Russian – C2

German – A2

Georgian – native

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

My extensive experience within the Heart Failure Association, European Cardiology Society, and the Georgian Heart Failure Association uniquely positions me to contribute meaningfully to the Heart Failure Board. As the founder of the Georgian Heart Failure Association, I spearheaded initiatives to raise awareness, improve treatment, and enhance education in Georgia and the region. Notably, I organized the first-ever Heart Failure Forum and Master Courses in Heart Failure, featuring expert speakers in the field. These events provided invaluable learning opportunities and fostered collaboration among healthcare professionals, ultimately driving advancements in heart failure management.

Within the European Cardiology Society, I have actively participated in conferences, workshops, and collaborative projects focused on heart failure research and clinical practice. My involvement has allowed me to stay abreast of the latest developments in the field and forge connections with renowned experts, further enhancing my ability to contribute effectively to the Heart Failure Board.

Drawing on this rich background, I am committed to leveraging my experience and networks to advance the mission of the Heart Failure Board, driving innovation, and improving outcomes for patients worldwide.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

Dear Selection Committee,

I am deeply motivated to join the Heart Failure Board due to my fervent commitment to advancing cardiac care. With a blend of clinical experience and a profound passion for improving patient outcomes, I am eager to contribute to the board's mission of enhancing heart failure management strategies. My dedication to continuous learning and collaboration aligns seamlessly with the dynamic environment of the Heart Failure Board. I am inspired by the opportunity to work alongside esteemed professionals, leveraging diverse perspectives to address complex challenges in heart failure treatment and prevention. Joining the board represents a pivotal step in my career journey, allowing me to actively shape the future of cardiac healthcare while making a meaningful difference in the lives of patients worldwide. Furthermore, my participation is vital for improving awareness about heart failure, treatment, emphasizing the importance of early diagnosis, and promoting appropriate treatment is commendable, especially in a region like Georgia, Armenia, Azerbaijan and East Asia where such initiatives can significantly impact public health outcomes.

My involvement in organizing such events helps facilitate knowledge sharing, best practices, and professional development among healthcare professionals and stakeholders involved in the prevention and management of heart failure. By raising awareness about the importance of early detection and treatment, contributing to improving patient outcomes and quality of life for individuals affected by heart failure. Continuing to organize in relevant conferences, forums, and educational seminars,

Absolutely, ensuring equal care for everyone without discrimination based on race, religion, orientation, or any other factor is a fundamental principle that drives the missions of the Heart Failure Association, the European Cardiology Society, and the Georgian Heart Failure Association. By prioritizing inclusivity and diversity in healthcare delivery, these associations aim to decrease inequality and promote equitable access to high-quality heart failure management regardless of background or identity.

Through advocacy, education, and community engagement initiatives, these associations work tirelessly to address disparities in heart failure care, raise awareness about the importance of cultural competence and sensitivity in healthcare settings, and advocate for policies that promote equitable access to treatment and resources for all individuals affected by heart failure.

By fostering an environment of inclusivity and respect, these associations not only enhance patient care but also contribute to building healthier and more resilient communities where everyone has the opportunity to lead healthy and fulfilling lives, regardless of their background or circumstances.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

Combining a position on the Heart Failure Board with daily clinical and research responsibilities requires effective time management and delegation skills. By prioritizing tasks and leveraging support systems, I aim to ensure a seamless integration of my board duties with my clinical and research workload. I plan to allocate specific time slots for board meetings, strategic planning sessions, and collaborative projects while maintaining flexibility to accommodate urgent clinical needs and research deadlines. Additionally, I will delegate tasks when possible, empower team members, and leverage technology for efficient communication and coordination. By fostering a balanced approach and aligning priorities, I am confident in my ability to fulfill both roles effectively, contributing meaningfully to the Heart Failure Association while advancing patient care and research endeavors.